- Apr 2, 2009
- 5,171
- 13,288
- 66
In a July 26 report to investors, analysts at CLSA estimated the following financial losses for Reynolds American on e-cigarettes.
2013 - $85M
2014 - $250M
2015 - $185M
2016 - $140M
2017 - $95M
If/when FDA approves Reynolds PMTA applications for Vuse (and/or other Reynolds vapor products) in 2018 (when sales of all vapor products will be banned), those financial losses could quickly turn into huge financial gains.
Edit update on July 29
CLSA also estimated the following vapor product revenue for Reynolds
(note that estimated losses by Reynolds factored in the following)
2013 - $5M
2014 - $50M
2015 - $125M
2016 - $220M
2017 - $235M
CLSA also issued a similar report for Altria, that estimate the following financial losses for its vapor products.
2013 - $76M
2014 - $179M
2015 - $166M
2016 - $147
2017 - $104M
CLSA also estimated the following revenue for Altria vapor sales, which was already factored into their loss estimates above).
2013 - $5M
2014 - $50M
2015 - $65M
2016 - $75M
2017 - $85M
2013 - $85M
2014 - $250M
2015 - $185M
2016 - $140M
2017 - $95M
If/when FDA approves Reynolds PMTA applications for Vuse (and/or other Reynolds vapor products) in 2018 (when sales of all vapor products will be banned), those financial losses could quickly turn into huge financial gains.
Edit update on July 29
CLSA also estimated the following vapor product revenue for Reynolds
(note that estimated losses by Reynolds factored in the following)
2013 - $5M
2014 - $50M
2015 - $125M
2016 - $220M
2017 - $235M
CLSA also issued a similar report for Altria, that estimate the following financial losses for its vapor products.
2013 - $76M
2014 - $179M
2015 - $166M
2016 - $147
2017 - $104M
CLSA also estimated the following revenue for Altria vapor sales, which was already factored into their loss estimates above).
2013 - $5M
2014 - $50M
2015 - $65M
2016 - $75M
2017 - $85M
Last edited: